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Abstract
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized 
by chronic hyperglycemia and increased risk of cardiovascular disease (CVD). It 
results from multiple defects that lead to defective regulation of the blood glucose 
and requires continuous medical care with multifactorial risk-reduction strategies 
beyond glycemic control. Multiple groups of drugs have been approved in the past 
decades that work through different mechanisms. Apart from their limited efficacy 
in reducing cardiovascular outcome, most of them are neutral, and some may even 
increase mortality from CVDs such as rosiglitazone. The kidney has an important 
role in glucose regulation that was only recently targeted for drug development. 
Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) are a new class of oral anti-
hyperglycemic (OAH) agents that mainly act by preventing the reabsorption of 
filtered glucose by renal convoluted tubules. By their insulin-independent unique 
mechanism of action, SGLT2-I result in treating hyperglycemia while avoiding 
hypoglycemia, promote weight loss, reduce blood pressure, and, more importantly, 
decrease the risk of major adverse cardiovascular events (MACE). Therefore, 
SGLT2-I address fundamental aspects of the unmet needs of T2DM management 
that most of the other OAH failed to resolve. The main side effects of SGLT2-I are 
slight increase in the incidence of genital mycotic infections (GMI) and euglycemic 
ketoacidosis (EKA) along with increased risk of lower limb amputations, which has 
been reported with some but not all agents of this class.
Keywords: type 2 diabetes mellitus, SGLT2 inhibitors, hyperglycemia,  
cardiovascular disease, mycotic infections, euglycemic ketoacidosis
1. Introduction
T2DM is a chronic progressive metabolic disease characterized by chronic 
hyperglycemia and increased risk of CVDs that result from defective regulation of 
the blood glucose and requires continuous medical care with multifactorial risk-
reduction strategies beyond glycemic control [1].
The magnitude of the problem can be assessed from the report of International 
Diabetes Federation (IDF) Atlas, where it was estimated that in 2017 there were 
451 million people (age 18–99 years) with diabetes mellitus (DM) worldwide and 
that almost half of all people (49.7%) living with DM are undiagnosed [2]. More 
alarmingly, the projected figures for the prevalence of DM according to the same 
IDF report are expected to increase to 693 million by year 2045. In addition, there 
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was an estimated 374 million people with impaired glucose tolerance (IGT), and in 
2017 sadly, approximately 5 million deaths worldwide were attributable to DM. The 
global healthcare expenditure on people with DM was estimated to be USD 850 
billion in 2017 [2]. Therefore, it is obvious that T2DM comes with a huge burden 
of morbidity and mortality and this is mainly due to the development of diabetes-
specific microvascular complications and accelerated atherosclerotic macrovascular 
disease [3, 4].
T2DM is the seventh leading cause of death in the United States, and the esti-
mate of the World Health Organization that T2DM-related mortality is expected to 
double in number by year 2030 if not treated properly further raises the alarm [5].
Improving glycemic control in people with DM not only substantially reduces 
their risk of microvascular complications and CVDs but also ameliorates the 
metabolic dysfunctions that contribute to the progressive nature and course of 
the disease. Evidence from United Kingdom Prospective Diabetes Study (UKPDS) 
showed that 1% reduction in glycosylated hemoglobin (HbA1C) was associated with 
relative risk reduction of 14% in fatal and nonfatal myocardial infarctions, 12% in 
fatal and nonfatal stroke, and 16% in heart failure [6].
While intensive glycemic control has been shown to substantially reduce the risk 
of microvascular complications, its value in reducing macrovascular complications 
that was previously reported 20 years after the end of UKPDS has recently been put 
in doubt after the ACCORD and ADVANCE Trials, which either showed increased 
risk of death or no benefit [7–9].
The UKPDS was the first study to show unequivocally that in patients with 
newly diagnosed T2DM, lowering blood glucose with intensive therapy to a median 
HbA1C of 7.0% was associated with 25% reduction in the rate of microvascular 
complications [7].
Moreover, after 10 years of follow-up post UKPDS, the benefits continued with 
regard to reduction in microvascular complication, and the reduction in macrovas-
cular events was clearer [10].
Notable are the results of ACCORD, ADVANCE, and the Veterans Affairs 
Diabetes Trial (VADT) studies in patients with advanced T2DM, and either known 
CVD or multiple CVD risk factors showed that lowering blood glucose (HbA1C 
levels 6.4–6.9%) delayed the onset or slowed the progression of microvascular 
complications, but there was no significant reduction in CVD outcomes [8, 9, 11]. 
On the other hand, the ACCORD study suggests that less intensive therapy may be 
more appropriate in patients with T2DM and high risk of CVDs because intensive 
therapy to target HbA1C levels (6.4–7.5) was associated with a 22% increased risk of 
all-cause mortality [9].
Based on what we have learned from these studies, the American Diabetes 
Association and the European Association for the Study of Diabetes guideline 
suggest reducing HbA1C levels to around 7%, but in younger patients with short 
duration of diabetes and no significant heart diseases, HbA1C levels can be reduced 
to less than 6.5%. In older patients and those with advanced CVD and limited life 
expectancy, less stringent HbA1C levels around 8% may be appropriate [3].
Hypoglycemia, weight gain, and progressive beta-cell failure are the major limit-
ing factors for intensive glycemic control approach and in achieving the proposed 
HbA1C goals [12].
The efficacy of the available OAHs and their effectiveness in the management of 
T2DM were reported in 2013 according to which and despite availability of several 
therapeutic options, 33–49% of patients fail to meet the targets for control of 
glycemia, blood pressure, or cholesterol and only a minority, around 14%, were able 
to meet targets for all three measures [13].
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Apart from the limited efficacy of some OAHs in reducing CV risk, most of 
these agents are neutral when it comes to CVD risk reduction and some may even 
increase mortality from CVDs.
Therefore, for some time, T2DM unmet needs remained unresolved, and the 
need for innovation continued. For some experts in the field, it was suggested that 
newer OAHs should be so unique in their properties, namely, addressing the unmet 
needs and filling the gaps of the available OAHs such as weight gain, hypoglycemia, 
and CV safety to pass the test of FDA approval after the rosiglitazone story which 
was withdrawn from the market in 2008 because of its association with increased 
risk of CVDs [14]. Following rosiglitazone incident, the FDA mandated cardiovas-
cular outcome trials on all newer OAH agents [15].
T2DM treatment requires individualized management with consideration of a 
number of patient factors. These include the degree of HbA1c reduction needed, risk 
of hypoglycemia, the side effect profile of medications, comorbid medical condi-
tions, and the ability of patients to adhere to the medication regimen along with their 
preferences. Development of novel drugs with newer and complimentary mecha-
nisms of action is needed to address the unwanted side effects and limitations of most 
of the old OAH agents, namely, the risk of hypoglycemia, weight gain, durability, and 
CV safety profile. Availability of newer medications with such profiles will simplify 
therapy and enhance patient adherence, especially in this era of increasing obesity.
Among newer classes of drugs, SGLT2-I hold great promise, and several agents 
from this group have already been approved by the US FDA and elsewhere for treat-
ment of T2DM. They have a novel therapeutic mechanism of action when compared 
with other drugs available for T2DM management. The main site of action of 
SGLT2 inhibitors is in kidneys—a site which plays a major role in glucose homeosta-
sis and has never been explored before.
2. Glucose homeostasis
Glucose is an essential and principal fuel source for cellular metabolism in 
the human body and is the main energy resource for the central nervous system, 
muscles, and fat—and insulin plays a key role in its effective utilization. The 
glucose homeostasis is rapidly adjusted in response to physiological changes such 
as food intake, exercise, and acute stress, and its blood level is adjusted by control 
of absorption of glucose, its metabolism in the liver, its excretion by kidneys, and 
uptake into muscles and adipose tissue. Functions of various proteins associated 
with regulation of glucose metabolism and homoeostasis get affected by diseases 
such as DM and hepatic disorders [16].
2.1 Handling of glucose in the intestine
After ingestion of carbohydrate-rich diet, blood glucose is regulated in response 
to the increase in glucose concentration in the intestinal lumen and in response to 
the increase in blood glucose level. The increase in glucose levels in the lumen of the 
small intestine provides a signal for the upregulation of intestinal glucose absorp-
tion [17] and leads to secretion of gut hormones such as glucose-dependent insu-
linotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1), which increase the 
glucose-dependent stimulation of insulin secretion from the pancreatic β-cells and 
also influence appetite [18]. Insulin reduces glucagon secretion by acting on pancre-
atic alpha cells and also reduces blood glucose level by increasing glucose uptake in 
fat and muscle cells and changing glucose metabolism in the liver [1].
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2.2 Glucose transport across plasma membrane
Being a highly polar molecule, glucose is unable to cross the lipid bilayer of the 
plasma membrane of all living cells; therefore, transport proteins within the cell 
membrane are required to facilitate glucose transport from the extracellular to the 
intracellular space.
Two distinct groups of glucose transporters belonging to solute carrier gene series 
(SLC) containing more than 50 transporter families have been described [19]. The first 
one is facilitated glucose transporters (GLUT) which is encoded by the SLC2 family of 
transporters GLUT1–4 and GLUT6–12, which help in passive transportation of glucose 
from the extracellular to the intracellular space along its chemical gradient without 
consuming any energy and equilibrate glucose concentration on both sides of mem-
brane. The other one is sodium-glucose cotransporters (SGLTs) which are encoded by 
SLC5 family of transporters SGLT1–6 which actively transport glucose across plasma 
membranes against its concentration gradient. This process requires energy which is 
provided by simultaneous coupled transportation of sodium along its concentration 
gradient [19]. In this way, SGLTs help in concentrating glucose inside the cells.
The two principal sites of action of SGLTs are the intestine and kidney where 
they mediate glucose transportation across the intestinal lumen and the epithelial 
cells in the proximal renal tubules, respectively [20].
2.3 Handling of glucose by the kidney
The kidney plays an important role in glucose homeostasis by the process of fil-
tration and reabsorption. Renal glomeruli filter approximately 180 liters of plasma 
daily which translates into filtration of approximately 180 g of glucose. In normal 
healthy subjects, all of this glucose is reabsorbed completely so that virtually no 
glucose is excreted in urine. Around 90% of the filtered renal glucose is reabsorbed 
in early part (S1) of proximal convoluted tubules by low-affinity high-capacity 
SGLT2. High-affinity low-capacity SGLT1 in distal straight segment (S3) of the 
proximal tubules reabsorbs the remaining 10% of the filtered renal glucose [21].
This process of glucose reabsorption is achieved by active Na+ removal at baso-
lateral surface by the Na+/K+-ATPase which generates the electrochemical driving 
force for apical glucose entry via Na+-driven SGLTs. Reabsorbed glucose exits from 
the basolateral surface of the cells along its concentration gradient primarily via 
GLUT2 and reenters the bloodstream [21].
When blood glucose level exceeds 200 mg/dL, the excess glucose starts appear-
ing in urine as renal transport maximum (Tm) of glucose is reached. The blood 
glucose level at which Tm is reached is called threshold and is around 300 mg/dL 
in healthy nondiabetic individuals, but glucose starts appearing in urine at around 
200 mg/dL due to heterogeneity of individual nephrons in their Tm property and 
mismatch between glomerular filtration and tubular reabsorption of glucose. This 
safety valve-like action prevents extreme hyperglycemia [22].
The Tm of the proximal tubules on average is around 375 mg/minute although it 
shows inter-individual variations. The filtered glucose load is directly proportional 
to blood glucose concentration. In normal nondiabetic individuals, the filtered 
glucose load is less than 375 mg/minute; therefore, the entire amount is reabsorbed, 
and their urine is free of any glucose. This process has survival benefits as it allows 
the kidneys to conserve glucose and can be viewed as an adaptive mechanism. 
In patients with T2DM, the filtered load may exceed 375 mg/minute; therefore, 
the Tm is exceeded, and all glucose in excess of the Tm spills over in urine [21]. In 
T2DM subjects, this adaptive mechanism becomes maladaptive. The increased 
expression of SGLT1/SGLT2 occurring in DM subjects results in increased renal 
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glucose reabsorption which ultimately leads to maintenance of a state of persistent 
hyperglycemia [23, 24]. The tubular growth leads to increased Tm for glucose which 
further exacerbates hyperglycemia [22].
Based upon these facts, the contribution of the kidney in development and main-
tenance of state of hyperglycemia in T2DM is quite evident. Therefore, SGLT2-I 
provide a pathophysiologically rational and novel approach to its treatment.
3. Clinical effects of mutations in SGLT1 and SGLT2
Autosomal recessive mutations in SGLT1 lead to a disorder called glucose galac-
tose malabsorption (GGM). SGLT1 becomes nonfunctional, and infants with GGM 
develop severe watery diarrhea, dehydration, and metabolic acidosis that cease on 
diet free of glucose, galactose, and lactose [25].
In 1927, the first case of familial renal glycosuria was reported, in which a muta-
tion in gene for SGLT2 resulted in loss of glucose in urine ranging from 1 to 150 g 
per 1.73 m2 body surface areas per day. Almost 50 mutations have been identified 
so far leading to this condition which is characterized by urinary glucose excretion 
in the presence of normal plasma glucose levels and an absence of signs of general 
renal tubular dysfunction. Patients have normal oral glucose tolerance test and 
usually present with osmotic symptoms without any serious complications [26, 27]. 
The condition is not associated with any change in intravascular volume, serum 
glucose levels, or renal or bladder dysfunctions. These patients do not show higher 
incidence of kidney disease, DM, or urinary tract infections although those affected 
with severe forms of the disease may demonstrate activation of renin-angiotensin-
aldosterone axis as indirect evidence of volume contraction [20, 26, 27].
These observations further strengthen the belief that SGLT2-I could potentially 
be developed as safe OAH.
4. Sodium-glucose cotransporters
So far, six different SGLTs have been described; however, apart from SGLT1 
and SGLT2 which are well characterized, little is known about the function and 
clinical significance of the others [20]. Both SGLT1 and SGLT2 are large-membrane 
proteins consisting of 670 amino acids, and each has 14 transmembrane helical 
domains. The homology between SGLT1 and SGLT2 is around 58% (Table 1) [20].
Transporter Gene Substrate Distribution and localization
SGLT1 (SLC5A1) 22q12.3 Glucose, 
galactose
Intestine, trachea, kidney, heart, brain, testis, 
prostate
SGLT2 (SLC5A2) 16p12.p11 Glucose Kidney, brain, liver, thyroid, heart, muscle
SGLT3 (SLC5A4) 21q22.12 Glucose Intestine, testis, uterus, lung, brain, thyroid
SGLT4 (SLC5A9) 1p32 Glucose, 
mannose
Intestine, kidney, liver, brain, lung, trachea, 
uterus, pancreas
SGLT5 (SLC5A10) 17p11.2 Glucose, 
galactose
Renal cortex
SGLT6 (SLC5A11) 16p12.1 D-chiro-inositol Spinal cord, kidney, brain
Table 1. 
Genes, substrates, and distributions of SGLT [28].
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4.1 Sodium-glucose cotransporter 1 (SGLT1)
4.1.1 Locations of SGLT1
Studies have classically localized SGLT1 to the small intestine and the kidney 
where their pathophysiological roles are known in details [28].
Various other body organs such as the heart, lung, trachea, liver, skeletal muscle, 
gall bladder, rectum, colon, brain, blood vessels, breast, uterus, testis, and pancre-
atic alpha cells have shown mRNA level expression of SGLT1 [28–33].
4.1.2 Functional properties of SGLT1
SGLT1 transports one molecule of glucose or galactose together with two sodium 
ions. This stoichiometric ratio of 1:2 enables to raise the intracellular glucose level 
orders of magnitude above the corresponding extracellular concentration. The 
apparent Michaelis-Menten Km values for glucose and galactose at physiological 
extracellular sodium concentration and membrane potential are 0.5 and 1.0 mM, 
respectively. It has high affinity for both glucose and galactose but has a lower 
transport capacity (Tmax = 2 nmol/mg protein per minute) [28, 34].
4.1.3 Physiological functions of SGLT1
SGLT1 is highly expressed in the small intestine and is located in the brush 
border membrane (BBM) of the enterocytes and in endocrine cells of gut and the 
K- and L-cells which secrete GIP and GLP-1/GLP-2, respectively. SGLT1-mediated 
translocation of glucose is the rate-limiting step for small intestinal glucose absorp-
tion [17, 28, 29]. Absorbed glucose in the enterocytes is released across the basolat-
eral membrane and enters blood circulation via GLUT2. During bacterial infection, 
SGLT1 protects the small intestine from lipopolysaccharide-induced inflammation 
because of high luminal glucose concentrations [35].
In the kidney, SGLT1 is located at BBM of S3 segment of renal tubules and is 
responsible for the first and rate-limiting step in reabsorption of glucose which 
escaped SGLT2-mediated reabsorption in S1 and S2 segments. In normal healthy 
adults, it only absorbs around 10% of the filtered glucose load, but in DM patients 
with uncontrolled hyperglycemia, the fraction of SGLT1-mediated renal glucose 
absorption increases significantly. Similarly, in patients on SGLT2-I therapy, the 
fraction increases to around 50–70% [17, 28, 29]. SGLT1 may play a protective role 
during treatment with nephrotoxic drugs such as cisplatin [36].
SGLT1 mRNA has been detected in the frontal cortex, hypothalamus, and 
Purkinje cells of cerebellum and hippocampus in brains of human, rabbit, and rat 
[33, 37, 38]. It is mainly localized in the luminal membrane of the endothelial cells, 
and its location and functional activity suggests a pivotal role in securing energy 
supply to neurons during conditions of increased energy and glucose demand 
such as hypoxia and/or hypoglycemia. SGLT1-mediated neuronal glucose uptake is 
involved in glucose-induced neurotoxicity during ischemic stroke [39].
SGLT1 is located at the myocyte sarcolemma and in small blood vessels of the 
heart [29, 32]. SGLT1-mediated glucose uptake is of clinical significance as it leads 
to ATP generation by glycolysis during myocardial ischemia and/or hypoglycemia 
[40]. At the same time, it may increase toxic effects that are mediated by generation 
of reactive oxygen species (ROS) during hyperglycemia [41].
SGLTI1 mRNA has been detected in the lung, trachea, and bronchi, and its 
protein has been localized to alveolar type 2 cells and to the luminal membrane 
of bronchiolar Clara cells by immunohistochemistry [30, 31]. SGLT1-mediated 
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glucose absorption contributes to fluid absorption and may provide energy for 
surfactant production in alveolar type 2 cells as well as for mucin and surfactants in 
Clara cells [42].
Similarly, the human gall bladder and liver have shown the presence of SGLT1 
mRNA [29, 30]. Its expression at mRNA and protein level has been demonstrated in 
human pancreatic alpha cells; however, little is known about its functional role [30, 
31]. SGLT1 has also been expressed in activated T-lymphocytes of mice where it may 
have a possible role in immune reactions [43].
4.1.4 Regulation of SGLT1 expression
The complex process of regulation of activity and expression of SGLT1 occurs in 
a tissue-specific manner. In the small intestine, upregulation of SGLT1 expression 
occurs in response to high-salt and/or high-glucose diet through transcriptional reg-
ulation which is also responsible for the circadian periodicity of SGLT1 expression 
[44, 45]. Its expression gets upregulated in the small intestine in diabetics [46] and 
in response to bacterial infections [35], while downregulation of SGLT1 expression 
occurs during chronic intestinal inflammation [47].
4.2 Sodium-glucose cotransporter 2 (SGLT2)
4.2.1 Locations of SGLT2
In humans, SGLT2 is strongly expressed in the kidney where it has been local-
ized to the brush border membrane of the S1 and S2 segment of the proximal 
tubules. On the other hand, SGLT1 has been localized to the brush border mem-
brane of the S3 segment of proximal convoluted tubules of the kidney [28–30, 48].
Proteins and mRNA of SGLT2 have also been found in alpha cells of the pancreas 
[31]. In addition to the kidney and pancreas, small amount of SGLT2 mRNA have 
been identified in the testis, liver, lung, and cerebellum [21, 28–30, 48].
4.2.2 Functional properties
SGLT2 is highly selective for glucose over galactose. It has low affinity for 
glucose with Km = 2 mM but with high transport capacity with Tmax = 10 nmol/mg 
protein per minute and operates with a 1:1 stoichiometry of sodium and glucose. 
The apparent Michaelis-Menten Km values for glucose and sodium in human SGLT2 
are 5 and 25 mM, respectively [28].
4.2.3 Physiological functions of SGLT2
4.2.3.1 Functions of SGLT2 in the kidney
Details of the physiological functions of SGLT2 in the kidney have already been 
mentioned earlier in Section 2.3.
In T2DM, SGLT2-mediated reabsorption of glucose and sodium is increased and 
can be considered physiologically maladaptive as it prevents an increase in urinary 
glucose excretion at high blood glucose levels. The increase in proximal tubular 
sodium reabsorption leads to fall in the distal tubular sodium and chloride concen-
trations which result in glomerular hyperfiltration [49] and plays a central role in 
the development of diabetic nephropathy [50].
The triad of hyperglycemia, elevated GFR, and the increased proximal tubular 
glucose reabsorption altogether leads to increase in kidney size and volume which is 
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combined with glomerular hypertrophy, enlarged proximal tubules, inflammation, 
and interstitial fibrosis. These hyperglycemia-induced alterations lead to micro- 
and macroalbuminuria which culminate into renal failure [49].
4.2.3.2 Functions of SGLT2 in pancreatic alpha cells
During fasting when blood glucose level is low, several counter-regulatory 
responses are generated to increase and maintain blood glucose within normal 
range. Pancreatic alpha cells secrete glucagon which stimulates glycogenolysis and 
gluconeogenesis in the liver. Conversely, glucagon secretion is inhibited when blood 
glucose level increases after taking food [51]. Inhibition of glucagon secretion is 
mediated by paracrine effect of insulin and direct glucose-mediated regulation of 
glucagon secretion. In alpha cells, SGLT2-mediated glucose uptake is a critical step 
involved in direct regulation of glucagon secretion [31].
The expression of SGLT2 at mRNA level increases in alpha cells in obesity and 
prediabetes. Once T2DM develops, the glucotoxicity leads to decrease in its expres-
sion. The glucagon secretion blockage which normally occurs at high plasma glucose 
levels gets blunted due to downregulation of SGLT2 causing enhanced endogenous 
glucose production in the liver which further aggravates hyperglycemia [31].
4.2.4 Regulation of SGLT2
SGLT2 gene is located at chromosome 16 p11.2 and is expressed primarily in 
renal cortex. Various transcription factors are involved in regulation of SGLT2 such 
as SP-1, HNF1-alpha, and HNF4A, and their binding sites have been identified on 
SGLT2 promoter region [28].
High-sodium intake promotes urinary sodium and glucose excretion by increas-
ing plasma adiponectin level through stimulation of peroxisome proliferator-
activated receptor delta in adipose tissue. The enhanced adiponectin downregulates 
SGLT2 leading to reduced reabsorption of sodium and glucose. Due to hypergly-
cemia, this mechanism gets dampened in DM. Binding of SP-1 and HNF1-alpha at 
the promoter site is involved in this regulation [52], while HNF4A participates in 
glucose-dependent regulation of SGLT2 in alpha cells of the pancreas [31].
Activation of transcription factor NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) downregulates transcription of SGLT2 in the 
presence of hyperglycemia due to increase in ROS [53]. Sympathetic innervation 
has been found to be involved in transcriptional upregulation of SGLT2 in the 
kidney [54].
Posttranscriptional regulation of SGLT2 is yet to be understood well. Recently, 
it was found that the 17 kDa protein membrane-associated protein 17 (MAP17) 
upregulates functional activity of SGLT2 in the plasma membrane [55].
5. Development of SGLT inhibitors
Given the findings discussed in the above sections and considering the physi-
ological functions of SGLT1 and SGLT2, it was an obvious idea to use SGLT1 and 
SGLT2 inhibitors as OAHs. Targeting hyperglycemia by inhibiting intestinal and 
renal glucose reabsorption appeared to be a novel therapeutic strategy.
Phlorizin was discovered around 150 years ago, which is a chemical found in 
the root bark, leaves, shoots, and fruit of the apple tree, and soon thereafter it 
was found to increase renal glucose excretion in healthy human beings. Phlorizin 
is a naturally occurring competitive nonselective inhibitor of SGLT1 and SGLT2. 
9SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus
DOI: http://dx.doi.org/10.5772/intechopen.84152
In 1987, it was reported that subcutaneous phlorizin administration normalized 
plasma glucose profiles in insulin-resistant diabetic rats along with improving 
insulin sensitivity [56].
However, due to poor water solubility and poor oral bioavailability as it is 
metabolized to phloretin by glucosidase in gut and unselective SGLT1 and SGLT2 
inhibition, phlorizin was not an ideal therapeutic agent. It has low selectivity for 
SGLT2 compared to SGLT1.
T-1095 was the next agent developed but did not continue into clinical develop-
ment as it was again nonselective in nature and had safety concerns [57].
By modification in basic structure of phlorizin, other SGLT2-I were developed, 
including AVE-2268, remogliflozin, sergliflozin, and WAY-123783.
All of them have the glucoside moiety linked to a distal phenolic ring via an 
O-linkage. Due to susceptibility of O-linkage to degradation by β-glucosidases 
which reduced their utility, development of more metabolically stable C-linkage 
SGLT2 inhibitors was prompted with focus on increasing selectivity for SGLT2 
versus SGLT1. This led to discovery of dapagliflozin, canagliflozin, empagliflozin, 
ipragliflozin, BI 44847, and LX 4211 [58, 59].
6. Clinical effects of SGLT2 inhibitors in diabetes mellitus
Currently, there are seven SGLT2 inhibitors approved for clinical use. They are 
given orally and absorbed by the intestine. Due to higher selectivity for SGLT2 ver-
sus SGLT1, inhibition of intestinal SGLT1 can be avoided, though it is still possible 
at high oral doses. At pharmacological doses, their serum levels achieved are too low 
to inhibit SGLT1 in other organs (Table 2).
Clinical effects observed for different SGLT2-I will be described and discussed 
together for the sake of clarity.
6.1 Effects on diabetes and metabolism
In T2DM, upregulation of SGLT2 expression increases its Tm by around 20%. 
SGLT2-I is filtered in glomeruli and inhibits glucose reabsorption in S1 segment of 
proximal tubule leading to a reduction of 30–50% in Tm of SGLT2 [67].
In the presence of functional SGLT2, less than 10% of glucose is absorbed 
through SGLT1; therefore, it is expected that SGLT2 inhibitor therapy would lead to 
around 90% reduction in Tm but the observed decrease of only 30–50% in Tm can be 
explained by higher amount of SGLT1-mediated glucose reabsorption [70].
Compound Preparation strength available SGLT2/SGLT1 selectivity Reference
Dapagliflozin 5, 10 mg 1200 [60]
Canagliflozin 100, 300 mg 200 [61]
Empagliflozin 10, 25 mg 2500 [62]
Ertugliflozin 5, 15 mg 2000 [63]
Ipragliflozin 25, 50 mg 254 [64]
Luseogliflozin 2.5, 5 mg 1765 [65]
Tofogliflozin 20 mg 2900 [66]
Table 2. 
Preparation strength and SGLT2 versus SGLT1 selectivity of various approved SGLT2 inhibitors.
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During preclinical studies with animal models of diabetes as well as in clini-
cal studies with both T2DM and T1DM patients, it has been demonstrated that 
prolonged SGLT2-I therapy decreased fasting and prandial plasma glucose levels, 
reduced HbA1C, and improved oral glucose tolerance. They also exerted nephro-
protective effects, reduced blood pressure, and increased utilization of fatty acid 
substrates; thus, they also conferred metabolic benefits [68–73].
SGLT2-I have insulin-independent mechanism of action. They can be used both 
as monotherapy as well as in combination with other OAHs [74, 75]. Clinical trials 
have shown that SGLT2-I are effective when administered in combination with met-
formin [74, 76–78], metformin plus sulfonylurea [79], insulin [80], DPP4 inhibitors 
[77], and thiazolidinediones [75].
SGLT2-I do not increase the risk of hypoglycemia like other OAH agents. The 
filtered renal glucose load is directly correlated with plasma glucose level, and there 
is compensatory increase in SGLT1-mediated glucose reabsorption when SGLT2 is 
blocked [81]. The other mechanism preventing hypoglycemia is the glucagon secre-
tion from pancreatic alpha cells due to SGLT2 inhibition [31].
SGLT2-I therapy in patients with T2DM increases both plasma glucagon and 
endogenous glucose production. Despite such physiological changes, patients on 
SGLT2-I have lower plasma glucose levels than those receiving placebo, possibly 
because of increased glycosuria and improved insulin sensitivity [82, 83].
SGLT2-I administration changes body metabolism and shifts it to enhanced 
usage of fat for metabolic needs; consequently beta-hydroxybutyrate levels in 
plasma increase [69]. The metabolic inflexibility characteristically seen in patients 
with T2DM and nondiabetic insulin-resistant subjects is an inability to switch from 
predominantly fatty acid oxidation during fasting state to predominantly glucose 
oxidation in fed state [84]. Lack of variability in measured respiratory quotient 
(RQ ) between fasting and fed states has been observed as an evidence of metabolic 
inflexibility. SGLT2-I reduce whole body fasting RQ which is indicative of increased 
oxidation of fatty acids and amino acids, suggesting its partial restoration [85].
As a consequence of improved glucose homoeostasis, SGLT2-I may slow down 
glucotoxicity-mediated degeneration of beta cells and thus may also slow down 
the progression of T2DM. Experimental diabetic animal models on SGLT2-I have 
shown an improvement in both beta cell mass and functions [86]. Improvement in 
insulin sensitivity is another beneficial aspect [82, 83].
6.2 Effects on blood pressure
Increased urinary excretion of glucose and sodium leads to mild diuresis coupled 
with urinary sodium loss. Reduction of extracellular volume occurs which has a 
favorable effect on blood pressure, and the magnitude of the effect is most apparent 
in patients with preexisting hypertension [87].
Empagliflozin causes a reduction in systolic blood pressure (SBP) of 4–6 mmHg, 
whereas diastolic blood pressure (DBP) was similar to placebo with no increase in 
the heart rate [88]. Similarly, canagliflozin at 300 mg/day resulted in a reduction in 
SBP of 5.1 mmHg [89].
In analysis of 12 studies with dapagliflozin at 10 mg/day, reduction of 4.4 mmHg 
and 0.5 mmHg in SBP and DBP, respectively, was seen with no increase in the heart 
rate compared to placebo [90].
6.3 Effects on body weight
On SGLT2-I therapy, initial weight loss could result from osmotic diuresis. 
However, sustained weight loss over the period is a consequence of renal glucose 
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excretion leading to a caloric deficit of about 280 calories/day. This translates into 
decrease in body weight by 1–3 kg along with decreased visceral adiposity.
In the EMPA-REG trial, empagliflozin resulted in weight loss of about 2 kg 
[91]. The average weight loss achieved with dapagliflozin and canagliflozin stands 
between 1 and 3%, while other studies report a loss more than 5% [92, 93].
6.4 Effects on plasma lipids and plasma uric acid
SGLT2-I therapy has been associated with alteration in serum lipid profile. Small 
increase in low-density lipoprotein cholesterol (LDL) and high-density lipoprotein 
cholesterol (HDL) has been observed [76, 78, 94].
Any increase in serum cholesterol is considered to be a risk factor for the devel-
opment of heart failure and CVDs. However, it may not be relevant clinically, as 
empagliflozin has been shown to have a protective effect on MACE in EMPA-REG 
trial [91].
They also promote uric acid excretion and reduce uric acid level in the blood 
[94] which may contribute to their protective effect on the development of diabetic 
nephropathy observed in the EMPA-REG renal study [73, 80, 95].
6.5.1 Effects on cardiovascular disease
In EMPA-REG trial, empagliflozin has shown a lower risk for MACE as well as 
for cardiovascular death and has been found to be protective [88].
In CANVAS Program, canagliflozin has been found to reduce the risk of cardio-
vascular death or hospitalization for heart failure in patient with a history of T2DM 
and high CVD risk [96].
Lately, DECLARE-TIMI 58 trial demonstrated the CV safety of dapagliflozin 
in patients with T2DM who had or were at risk of CVDs. It was found to reduce 
hospitalization for heart failure as has been seen with other SGLT2-I [97].
Both empagliflozin and canagliflozin has got FDA approval for cardiovascular 
risk reduction in T2DM patients who are at high risk for such events. The mecha-
nism of cardiovascular protection exerted by SGLT2-I is unknown and seems to be 
glucose independent. Apart from improved glycemic control, the pleiotropic effects 
of SGLT2 inhibitors which include their ability to lower blood pressure, reduction in 
intraglomerular pressure and albuminuria, and amelioration of volume overload are 
all plausible protective mechanisms.
6.5.2 Effects on liver disease
T2DM affects metabolism in the liver and may manifest as hepatic steatosis and 
nonalcoholic steatohepatitis (NASH). NASH increases the risk of hepatocellular 
carcinoma and may result in liver cirrhosis also.
In preclinical studies on rodent models, SGLT2-I have been found to ameliorate 
nonalcoholic fatty liver disease (NAFLD) and NASH [70–72]. Although SGLT2-I 
are metabolized by the liver, studies involving patient with mild or moderate 
hepatic impairment showed dapagliflozin and empagliflozin were well tolerated and 
required no dose adjustments [98, 99].
Canagliflozin has shown improvement in serum aminotransferases and gamma-
glutamyl transferase levels in patients with T2DM [100]. In humans, ipragliflozin 
has shown reduction in liver fat in patients with T2DM and NAFLD [101]. 
Empagliflozin addition to the standard treatment of T2DM and NAFLD signifi-
cantly reduced liver fat, and improved ALT levels were seen [102].
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6.5.3 Effects on kidney disease
The kidney is the main target of action for SGLT2-I. Findings from animal 
models suggest it to be protective against development of diabetic nephropathy 
which exceeds the nephroprotective effect achieved secondary to improved glycemic 
control. During early stage of nephropathy, empagliflozin has been shown to prevent 
glomerular hyperfiltration, attenuate diabetes-associated renal growth, improve 
expression of inflammation markers, and reduce albuminuria in animal models [24].
Progression of nephropathy was slowed by luseogliflozin in T2DN rats, a genetic 
model of T2DM associated with severe nephropathy. It also prevents GFR decline 
and attenuates focal glomerulosclerosis, tubular necrosis, tubulointerstitial fibrosis, 
and progressive proteinuria [103].
Reduction in estimated GFR and nephroprotective effects has been reported 
with SGLT2-I in patients with DM [73, 80, 104]. Empagliflozin has been found to 
attenuate glomerular hyperfiltration in humans. It also reduces micro- and mac-
roalbuminuria, and the effects are independent of the improved glycemic effect 
[105]. In CANVAS trial, canagliflozin has been found to reduce albuminuria and the 
albumin-to-creatinine ratio when compared with placebo [106].
Results from a recent meta-analysis have indicated that SGLT2 inhibition pre-
serves renal function in patient with or without renal impairment. They slow down 
the progression of albuminuria and reduce urinary albumin-to-creatinine ratio in 
addition to reducing the risk of doubling of the serum creatinine level, initiation 
of kidney transplant, and death from kidney disease in patient with T2DM with or 
without history of renal impairment [107].
6.6 Risks for adverse drug effects and restrictions of application
6.6.1 Genital and urinary infections
Increased risk of GMI and urinary tract infections (UTI) are seen in DM due to 
hyperglycemia and glucosuria. SGLT2-I therapy has been associated with increased 
risks for GMIs and UTIs. Women otherwise also are more commonly affected than 
men, and SGLT2-I therapy further increases the risk in them.
When treated with canagliflozin for 4 months, around 10.4% of women and 
4.2% of men developed GMIs compared to 3.2% of women and 0.6% of men treated 
with placebo [108]. Most of the cases were of mild to moderate severity and could 
be treated with standard antifungal agents successfully.
Canagliflozin therapy in T2DM has been associated with UTIs in 8.7% of women 
compared to 7.7% treated with placebo. Figures for men were 1.4% versus 0.6%, 
respectively [109]. Similar findings were reported from pooled analysis of four 
studies (n = 2477) using empagliflozin. It was concluded that GMI were more com-
mon with empagliflozin than placebo (approximately 4 versus 1%, respectively); 
however, the frequency of UTI was about 8–9% for each [110].
Safety data from meta-analysis of eight studies using canagliflozin and dapagliflozin 
found that UTIs were more common with SGLT2-I as compared to other OAH (odds 
ratio, 1.42 [95% CI 1.06, 1.90]) as were GMI (odds ratio, 5.06 [95% CI 3.44, 7.45]) [111].
These studies suggests that most UTIs were mild to moderate, responded well to 
standard antimicrobial therapy, and rarely led to SGLT2-I discontinuation [112].
6.6.2 Euglycemic ketoacidosis
SGLT2-I therapy has been observed to be associated with small number of cases 
with EKA during treatment of T1DM and insulin-deficient T2DM [113].
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In CANVAS study, the incidence rates were 0.5 per 1000 patient years with 
canagliflozin 100 mg, 0.8 per 1000 patient years with canagliflozin 300 mg, and 0.2 
per 1000 patient years with comparator [114]. In the EMPA-REG trial, the incidence 
rates were 0.5 and 0.2 per 1000 patient years with empagliflozin 10 and 25 mg, 
respectively, and 1.2 per 1000 patient years in placebo group [88]. In DECLARE-
TIMI 58, using dapagliflozin, the corresponding rates were 0.3%, whereas 0.1% 
occurred among placebo-treated group [97].
Majority of the cases have been reported from clinical practice rather than trials 
and have occurred in patients on exogenous insulin. Reduction in insulin dose on 
starting SGLT2-I has been observed in them. Usually they present with classical 
diabetic ketoacidosis (DKA) features. However, some cases may present atypically 
with lower-than-expected hyperglycemia, and it can go unrecognized.
Almost all cases occurred in patients challenged with metabolically stressful 
events and common precipitants such as surgery, myocardial infarction, stroke, 
extensive exercise, severe infections, and prolonged fasting.
Low serum bicarbonate and positive urinary ketones may be suggestive but may 
be inaccurate; therefore, direct measurement of serum betahydroxybutyrate level 
to confirm the diagnosis of EKA has been recommended by the AACE. Once the 
diagnosis of EKA is confirmed, SGLT2-I should be discontinued, and DKA protocol 
should be followed [115].
The increased risk of EKA associated with SGLT2-I therapy may be explained 
by absolute or relative insulin deficiency, increased glucagon secretion, and 
stimulation of lipolysis and ketogenesis; however, other ketogenic factors are also 
involved [31, 69].
Most cases of EKA have occurred in patients with T1DM, which is an off-label 
use of these agents that is not an FDA-approved indication. Because insulin defi-
ciency may be the most important contributing factor, the AACE recommends 
against stopping insulin or decreasing the dose excessively. The risk of EKA has 
recently been shown in the EASE Trial to be dose dependent as lower doses of 
empagliflozin 2.5 mg were shown to be associated with lower rates of DKA, com-
pared to 10 and 25 mg, respectively [116].
Although not approved for treatment of T1DM and SGLT2-I use is still off-label 
in T1DM, the AACE encourages clinical trials due to their promising effect on 
glycemic control in this population [115].
6.6.3 SGLT2 inhibitors and risk of limb amputations
Canagliflozin significantly reduced the risk of CV events by 14% but increased 
the risk of lower limb amputation in patients with T2DM and high CVD risk (haz-
ard ratio 1.97) versus placebo as seen in CANVAS trial [114].
In the EMAP REG trial using empagliflozin, in T2DM patient with established 
CVD, the rate of lower limb amputation was similar to placebo group [88].
Recently in DECLARE-TIMI 58 trial, the rate of amputation was similar between 
the dapagliflozin- and placebo-treated patient (hazard ratio 1.09) [97].
In a recent report, canagliflozin, but not dapagliflozin or empagliflozin, was 
associated with a higher risk of amputation in a pharmacovigilance analysis using 
the US FDA Adverse Event Reporting System [117].
Presently the evidence may not be enough to explain a precise causal relation-
ship between canagliflozin and amputation. Neither the underlying mechanisms are 
currently known, nor do we know whether it is specifically related to canagliflozin. 
As amputation carries a negative impact on patient’s clinical course, understanding 
predisposing factors and mechanisms of amputation will be crucial to maximize the 
benefits of SGLT2 inhibitors in clinical practice [117].
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6.6.4 Effect on bone health
In CANVAS study, patients treated with canagliflozin had about six additional 
cases of bone fracture compared to those receiving placebo. However, such an effect 
could not be replicated in other trials of canagliflozin [118].
Canagliflozin is associated with a small but statistically significant decrease in 
total hip bone mineral density (BMD) but no statistically significant change in BMD 
at other sites and without any meaningful changes in most biomarkers of bone 
turnover [118].
No significant changes in bone density or increase in rate of fracture were 
observed with dapagliflozin in patients with DM and normal or mildly impaired 
renal function, but more fractures were observed in dapagliflozin-treated 
patients with moderate renal impairment (eGFR ≤30–60 mL/min/1.73 m2) [104]. 
Empagliflozin however did not show any clear evidence of increase fracture rates in 
people with T2DM [119].
Furthermore, the absence of SGLT2 in bone or bone marrow makes direct cause-
effect hypothesis unlikely. It is known that SGLT2-I induce osmotic diuresis leading 
to volume depletion which may increase the susceptibility to falls. An increase in 
fall-related fractures cannot be ruled out as a possible explanation. The exact reason 
and mechanism are unknown at this time and may possibly be related to factors 
extrinsic to bone health [28].
Pending further evidence, the US FDA has revised the label of canagliflozin with 
new warning in September 2015.
6.4.5 Restrictions of application
SGLT2-I are prescribed as once daily oral pill due to their long elimination half-
life. They are metabolized in the liver, and inactive metabolites are formed mainly 
due to glucuronidation.
They are also eliminated partially by renal excretion of parent drugs. Thus, 
dose adjustment is needed in patients with hepatic and/or renal disorders. They are 
contraindicated in severe chronic kidney disease.
7. Conclusion
SGLT2-I are a unique emerging class of OAH agents that has addressed fun-
damental aspects of the unmet needs that challenge physicians treating T2DM 
patients, such as increased risk of hypoglycemia and weight gain that are usually 
noticed with other agents such as insulin. On the contrary, SGLT2-I therapy in 
T2DM is associated with very low risk of hypoglycemia and also promotes weight 
loss. Moreover, SGLT2-I have been shown to reduce the risk of MACE, all-cause 
mortality, and hospitalization for heart failure. They have additional renal protec-
tive properties besides reducing SBP. In fact, their mode of action through preven-
tion of glucose reabsorption in the kidney makes them work independently from 
the pancreas, bypassing the problem of progressive beta cell failure that happens 
in most patients with T2DM over time, and this gives them longer durability. They 
can be used regardless of duration of disease and can be used as monotherapy as 
well as in combination as they have been shown to complement actions of other 
OAH agents including insulin. Considering their unique mechanism of action, they 
may be useful in impaired glucose tolerance and prediabetes also. The major side 
effects drawbacks of SGLT2-I is the increased rate of GMI. Another important side 
effect of SGLT2-I is EKA in T2DM patients during stress and following surgery as 
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well as in T1DM, which is an off-label use of these medications and seems to be dose 
dependent. Future drug developments should focus on finding the least effective 
dose with the least side effects.
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